Stemline Therapeutics Closes $59.6 Million Public Offering of Common Stock
January 26, 2018 10:21 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced the closing...
Stemline Therapeutics Prices $51.8 Million Public Offering of Common Stock
January 24, 2018 07:00 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced the pricing...
Stemline Therapeutics Announces Proposed Public Offering of Common Stock
January 22, 2018 16:01 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced that it...
Stemline Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
January 04, 2018 08:00 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers...
Stemline Therapeutics Presents Detailed SL-401 Pivotal Data in BPDCN at ASH and Kicks Off its BPDCN Awareness Campaign; Updated Results From Ongoing Trials in Additional Malignancies Also Presented
December 13, 2017 08:36 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
Stemline Therapeutics Announces Four SL-401 Presentations at Upcoming ASH Meeting
December 08, 2017 07:00 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 22nd Annual Meeting of the Society of Neuro-Oncology (SNO)
November 16, 2017 07:00 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Nov. 16, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
Stemline Therapeutics Reports Third Quarter 2017 Financial Results
November 09, 2017 16:01 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
Stemline Announces Four SL-401 Presentations at Upcoming ASH Meeting
November 01, 2017 09:02 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
Stemline Therapeutics Announces that Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Meets Primary Endpoint
October 31, 2017 07:00 ET
|
Stemline Therapeutics, Inc.
Detailed results will be presented at the ASH 2017 Annual Meeting (Dec. 9-12)Based on FDA feedback, BLA filing remains on-track Conference call scheduled for today, Tuesday, October 31, 2017 at 8:30AM...